Climate accounting body in battle over corporate ‘capture’, say staff - Financial Times

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta

2026-10-25

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ mo

2026-10-25

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progressi

2026-10-25

Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026 –

2026-10-25

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC - Financial Tim

2026-10-25